Chronic Utricaria or Hives - Drug Pipeline Landscape, 2022

Chronic Utricaria or Hives - Drug Pipeline Landscape, 2022

Urticaria is an itchy rash that appears on the skin. It may appear on one part of the body or be spread across large areas. Chronic urticaria is a mast cell-mediated condition characterized by the recurrent occurrence of urticaria and/or angioedema.

The welts that come with hives are caused by the release of immune system chemicals, such as histamine, into the bloodstream. The skin reaction may be triggered by heat or cold, sunlight, vibration, pressure on the skin, medical conditions, such as thyroid disease, infection, allergy, and cancer.

Symptoms of chronic hives includes batches of welts (wheals) that can arise anywhere on the body, welts that might be red, purple, or skin colored. Welts that vary in size, change shape, and appear and fade repeatedly, Itchiness (pruritus), which can be intense, painful swelling (angioedema) around the eyes, cheeks, or lips.

Doctors most often diagnose chronic urticaria by examining the rash. The tests include complete blood count, erythrocyte sedimentation rate and C reactive protein are important investigations for diagnosis of infections in urticaria.

The most common investigative treatments include antihistamines. These drugs ease itching, swelling and other allergy symptoms. Second-generation H1-antihistamines (e.g., cetirizine, loratadine, fexofenadine), taken regularly, are the first-line pharmacological treatment. Omalizumab given as a subcutaneous injection is a second-line adjunct therapy for CSU that is unresponsive to H1-antihistamines.

Symptoms can be eased through lifestyle changes and home remedies like comfortably cool shower or bath, wear loose, smooth-textured cotton clothing and protect your skin from the sun.

Report Highlights

Global Insight Service’s, Chronic Urticaria or Hives - Drug Pipeline Landscape, 2022 report provides an overview of the Chronic Urticaria or Hives pipeline drugs. This report covers detailed insights on Chronic Urticaria or Hives drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Chronic Urticaria or Hives pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.


The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.


The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.

List of Tables
List of Figures
1. Introduction
1.1 Chronic Urticaria or Hives – Pipeline Drugs, 2022-Coverage
2. Disease Overview – Chronic Urticaria or Hives
2.1 Causes
2.2 Signs and Symptoms
2.3 Diagnosis
2.4 Disease Management
3. Chronic Urticaria or Hives – Pipeline Drugs Development - Overview
3.1 Comparative Analysis by Stage of Development
3.2 Number of Products under Development by Companies, 2022
3.3 Products under Development by Companies, 2022
4. Assessment of Therapeutics
4.1 Assessment by Target
4.2 Assessment by Mechanism of Action
4.3 Assessment by Molecule Type
4.3 Assessment by Route of Administration
5. Drug Profiles
5.1 Clinical Stage Drugs - Phase III
5.1.1 AVT23
5.1.2 CT-P39
5.1.3 Dupilumab
5.1.4 LOU064
5.1.5 QGE031
5.1.6 SYN008 (China)
5.1.7 SYN008 (Global)
5.1.8 TEV-45779
5.2 Clinical Stage Drugs - Phase II
5.2.1 AK002
5.2.2 Benralizumab
5.2.3 CDX-0159
5.2.4 LP0190
5.2.5 SAR444671
5.2.6 ST-101
5.2.7 TAS5315
5.2.8 Tezepelumab
5.2.9 UB-221
5.3 Clinical Stage Drugs – Phase I
5.3.1 GI-301
5.3.2 OP2101
5.3.3 THB001
5.3.4 TLL018
5.4 Clinical Stage Drugs – Phase 0
5.4.1 Mepolizumab
5.5 Early Stage Drugs – Preclinical
5.5.1 BA 2101
5.5.2 KFRX04
5.5.3 Multipotent Mesenchymal Stem Cells
5.5.4 VB517
6. Key Regulatory Designations
7. Key Deals
8. Key Upcoming Milestones
9. Key Companies Involved
9.1 Allakos Inc
9.2 Alvotech
9.3 Amgen
9.4 AstraZeneca
9.5 Celldex Therapeutics
9.6 Celltrion
9.7 CSPC Baike (Shandong) Biopharmaceutical Co Ltd
9.8 GI Innovation
9.9 Hangzhou Highlightll Pharmaceutical Co Ltd
9.10 KeifeRx LLC
9.11 LEO Pharma
9.12 LUE Pharma Group Ltd
9.13 Mayo Clinic
9.14 Mirae Cell Bio Co Ltd
9.15 Novartis Pharmaceuticals
9.16 OrchestratePharma GmbH
9.17 Sanofi
9.18 Stero Biotechs Ltd
9.19 Synermore
9.20 Taiho Pharmaceutical Co Ltd
9.21 Teva Pharmaceuticals USA
9.22 Third Harmonic Bio, Inc
9.23 United BioPharma
9.24 ValenzaBio Inc
10. Dormant Drugs
10.1 Inactive Drugs
10.2 Discontinued Drugs
11. Appendix
List of Tables
Table 1. 2 Number of Products under Development by Companies
Table 1. 3 Products under Development by Companies
Table 1. 4 Products by Targets
Table 1. 5 Products by Mechanism of Action
Table 1. 6 Products by Molecule Type
Table 1. 7 Products by Route of Administration
Table 2.1 Clinical Trial Details - CT-P39/Celltrion
Table 2.2 Clinical Trial Details - Dupilumab/Sanofi
Table 2.3 Clinical Trial Details - LOU064/Novartis Pharmaceuticals
Table 2.4 Clinical Trial Details - QGE031/Novartis Pharmaceuticals
Table 2.5 Clinical Trial Details - SYN008 (Global)/Synermore
Table 2.6 Clinical Trial Details - TEV-45779/Teva Pharmaceuticals USA
Table 2.7 Clinical Trial Details - AK002/Allakos Inc
Table 2.8 Clinical Trial Details - Benralizumab/AstraZeneca
Table 2.9 Clinical Trial Details - CDX-0159/Celldex Therapeutics
Table 2.10 Clinical Trial Details - SAR444671/Sanofi
Table 2.11 Clinical Trial Details - ST-101/Stero Biotechs Ltd
Table 2.12 Clinical Trial Details - SYN008 (China)/CSPC Baike (Shandong) Biopharmaceutical Co., Ltd
Table 2.13 Clinical Trial Details - TAS5315 /Taiho Pharmaceutical Co., Ltd
Table 2.14 Clinical Trial Details - Tezepelumab/Amgen
Table 2.15 Clinical Trial Details - UB-221/United BioPharma
Table 2.16 Clinical Trial Details - OP2101/OrchestratePharma GmbH
Table 2.17 Clinical Trial Details - THB001/Third Harmonic Bio, Inc
Table 2.18 Clinical Trial Details - TLL018/Hangzhou Highlightll Pharmaceutical Co., Ltd
Table 2.19 Clinical Trial Details - Mepolizumab/GlaxoSmithKline
Table 3. 1 Regulatory Designations
Table 4. 1 Inactive Drugs
Table 4. 2 Discontinued Drugs
List of Figures
Figure 1. 1 Number of Products under Development for Chronic Urticaria or Hives, 2022
Figure 1. 2 Products by Top 5 Targets and Stage of Development for Chronic Urticaria or Hives, 2022
Figure 1. 3 Products by Top 5 Mechanism of Action and Stage of Development for Chronic Urticaria or Hives, 2022
Figure 1. 4 Products by Top 5 Molecule Type and Stage of Development for Chronic Urticaria or Hives, 2022
Figure 1. 5 Products by Top 5 Route of Administration and Stage of Development for Chronic Urticaria or Hives, 2022

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings